Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28405346 | 1.00 | ACE (0.48) | ACEELANENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15123250 | 0.92 | FKBP1A (0.45) | ACEELANEPTPN1HTR2C | |
| SCHEMBL15123248 | 0.92 | FKBP1A (0.45) | ACEELANEPTPN1HTR2C | |
| SCHEMBL11285685 | 0.87 | ACE (0.51) | ACENPC1RAB9ASMN1; SMN2HTR2C | |
| SCHEMBL11196452 | 0.87 | ACE (0.51) | ACENPC1RAB9ASMN1; SMN2HTR2C | |
| SCHEMBL15133222 | 0.86 | ELANE (0.42) | ELANENPC1RAB9ASMN1; SMN2PTPN1 | |
| SCHEMBL4435031 | 0.83 | ACE (0.61) | ACENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7270216 | 0.83 | ACE (0.61) | ACENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7271391 | 0.83 | ACE (0.57) | ACENPC1RAB9ASMN1; SMN2HTR2C | |
| SCHEMBL7271397 | 0.83 | ACE (0.57) | ACENPC1RAB9ASMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9474779-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | ACE 2416/4885ELANE 620/4885NPC1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.